Your browser doesn't support javascript.
loading
Incidence of and Risk Factors for Histologically Confirmed Solid Benign Tumors Among Long-term Survivors of Childhood Cancer.
Kok, Judith L; Teepen, Jop C; van der Pal, Helena J; van Leeuwen, Flora E; Tissing, Wim J E; Neggers, Sebastian J C M M; Loonen, Jacqueline J; Louwerens, Marloes; Versluys, Birgitta; van den Heuvel-Eibrink, Marry M; van Dulmen-den Broeder, Eline; Jaspers, Monique M W; van Santen, Hanneke M; van der Heiden-van der Loo, Margriet; Janssens, Geert O; Maduro, John H; Bruggink, Annette H; Jongmans, Marjolijn C; Kremer, Leontien C M; Ronckers, Cécile M.
Afiliación
  • Kok JL; Department of Pediatric Oncology, Emma Children's Hospital, Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam, the Netherlands.
  • Teepen JC; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • van der Pal HJ; Department of Pediatric Oncology, Emma Children's Hospital, Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam, the Netherlands.
  • van Leeuwen FE; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Tissing WJE; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Neggers SJCMM; Department of Epidemiology and Biostatistics, the Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Loonen JJ; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Louwerens M; Department of Pediatric Oncology/Hematology, University of Groningen/Beatrix Children's Hospital, University Medical Center Groningen, Groningen, the Netherlands.
  • Versluys B; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • van den Heuvel-Eibrink MM; Department of Pediatric Oncology/Hematology and Medicine section Endocrinology, Sophia Children's Hospital/Erasmus Medical Center, Rotterdam, the Netherlands.
  • van Dulmen-den Broeder E; Department of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Jaspers MMW; Department of Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands.
  • van Santen HM; Department of Pediatric Oncology and Hematology, Wilhelmina Children's Hospital/ University Medical Center Utrecht, the Netherlands.
  • van der Heiden-van der Loo M; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Janssens GO; Department of Pediatric Oncology/Hematology, Sophia Children's Hospital/Erasmus Medical Center, Rotterdam, the Netherlands.
  • Maduro JH; Department of Pediatric Oncology/Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • Bruggink AH; Department of Medical Informatics, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
  • Jongmans MC; Department of Pediatric Endocrinology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Kremer LCM; Dutch Childhood Oncology Group, Utrecht, the Netherlands.
  • Ronckers CM; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
JAMA Oncol ; 5(5): 671-680, 2019 May 01.
Article en En | MEDLINE | ID: mdl-30920605
ABSTRACT
IMPORTANCE Survivors of childhood cancer (CCSs) face risk of developing subsequent tumors. Solid benign tumors may be cancer precursors; benign tumors and cancers may share etiologic factors. However, comprehensive data on the risk for solid benign tumors are lacking.

OBJECTIVE:

To quantify the incidence of and treatment-related risk factors for histologically confirmed solid nonskin benign tumors among CCSs. DESIGN, SETTING, AND

PARTICIPANTS:

This record linkage study involves the Dutch Childhood Oncology Group-Long-Term Effects After Childhood Cancer (DCOG-LATER) cohort of 6165 individuals diagnosed with childhood cancer at younger than 18 years from January 1, 1963, through December 31, 2001, in 7 Dutch pediatric centers and who survived at least 5 years after the diagnosis. Study groups eligible for record linkage from 1990 onward included 5843 CCSs (94.8%) and 883 siblings. Benign tumors were identified from the population-based Dutch histopathology and cytopathology registry (PALGA). Follow-up was completed on May 1, 2015. Data were analyzed from January 1, 1990, through May 1, 2015. MAIN OUTCOMES AND

MEASURES:

Cumulative incidence of any subsequent benign tumor for cohort strata and multivariable Cox proportional hazards regression models (hazard ratios [HRs]) were used to evaluate potential risk factors for 8 major benign tumor subtypes.

RESULTS:

Of the 5843 eligible CCSs (55.9% male), 542 (9.3%) developed a histologically confirmed subsequent benign tumor after a median follow-up of 22.7 years (range, 5.0-52.2 years). Among women, abdominopelvic radiotherapy inferred dose-dependent increased risks for uterine leiomyoma (n = 43) for doses of less than 20 Gy (HR, 1.9; 95% CI, 0.5-7.0), 20 to less than 30 Gy (HR, 3.4; 95% CI, 1.1-10.4), and at least 30 Gy (HR, 5.4; 95% CI, 2.4-12.4) compared with no abdominopelvic radiotherapy (P = .002 for trend). High-dose radiotherapy to the trunk was not associated with breast fibroadenoma (n = 45). Of 23 osseous and/or chondromatous neoplasms, 16 occurred among leukemia survivors, including 11 after total body irradiation (HR, 37.4; 95% CI, 14.8-94.7). Nerve sheath tumors (n = 55) were associated with radiotherapy (HR at 31 years of age, 2.9; 95% CI, 1.5-5.5) and a crude indicator of neurofibromatosis type 1 or 2 status (HR, 5.6; 95% CI, 2.3-13.7). Subsequent risk for benign tumors was higher than the risks for subsequent nonskin solid malignant neoplasms and for benign tumors among siblings. CONCLUSIONS AND RELEVANCE This record linkage study uses a unique resource for valid and complete outcome assessment and shows that CCSs have an approximately 2-fold risk of developing subsequent benign tumors compared with siblings. Site-specific new findings, including for uterine leiomyoma, osteochondroma, and nervous system tumors, are important to enable early diagnosis; this information will be the first step for future surveillance guidelines that include some benign tumors in CCSs and will provide leads for in-depth etiologic studies.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Supervivientes de Cáncer / Neoplasias Tipo de estudio: Etiology_studies / Guideline / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: JAMA Oncol Año: 2019 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Supervivientes de Cáncer / Neoplasias Tipo de estudio: Etiology_studies / Guideline / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: JAMA Oncol Año: 2019 Tipo del documento: Article País de afiliación: Países Bajos